시장보고서
상품코드
1242540

세계의 엑소좀 시장

Exosomes

발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 엑소좀 시장은 2030년에 20억 달러에 도달

COVID-19 후의 변화한 비즈니스 환경에서 2022년에 6억 9,970만 달러로 추정되는 세계의 엑소좀 시장은 2022-2030년 CAGR 14.3%로 성장하며, 2030년에는 20억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 암은 CAGR 16.4%를 기록하며, 분석 기간 종료시에는 8억 3,400만 달러에 달할 것으로 예측됩니다. 팬데믹 후 회복을 고려하여 신경변성질환 분야의 성장은 향후 8년간 CAGR이 13.7%로 수정되었습니다.

미국 시장은 2억 1,190만 달러, 중국은 CAGR 13.5%의 성장을 예측

미국의 엑소좀 시장은 2022년에 2억 1,190만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2022-2030년 CAGR이 13.5%에 달하며, 2030년에는 3억 4,400만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 2022-2030년 각각 12.6%와 12%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 10.3%로 성장할 것으로 예측되고 있습니다.

조사 대상 기업의 예

  • Danaher Corporation
  • Diagenode SA
  • FUJIFILM Holdings Corporation
  • Hitachi Chemical Co America Ltd.
  • Lonza Group Ltd.
  • MBL International Corporation
  • Miltenyi Biotec GmbH
  • Novus Biologicals LLC
  • QIAGEN GmbH
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계의 기타 지역

제4장 경쟁

KSA 23.04.12

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Exosomes Market to Reach $2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Exosomes estimated at US$699.7 Million in the year 2022, is projected to reach a revised size of US$2 Billion by 2030, growing at aCAGR of 14.3% over the period 2022-2030. Cancer, one of the segments analyzed in the report, is projected to record 16.4% CAGR and reach US$834 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Neurodegenerative Diseases segment is readjusted to a revised 13.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $211.9 Million, While China is Forecast to Grow at 13.5% CAGR

The Exosomes market in the U.S. is estimated at US$211.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$344 Million by the year 2030 trailing a CAGR of 13.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.6% and 12% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Select Competitors (Total 46 Featured) -

  • Danaher Corporation
  • Diagenode SA
  • FUJIFILM Holdings Corporation
  • Hitachi Chemical Co America Ltd.
  • Lonza Group Ltd.
  • MBL International Corporation
  • Miltenyi Biotec GmbH
  • Novus Biologicals LLC
  • QIAGEN GmbH
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Exosomes - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Neurodegenerative diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Neurodegenerative diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cardiovascular diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Cardiovascular diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Infectious diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Exosomes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Exosomes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: USA 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Canada 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Canada 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • JAPAN
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Japan 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Japan 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • CHINA
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: China 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • EUROPE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Europe 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Exosomes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 37: Europe 8-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • FRANCE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: France 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 43: France 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • GERMANY
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Germany 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Italy 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Italy 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • UNITED KINGDOM
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: UK 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: UK 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Rest of World 8-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2023 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Rest of World 8-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2023 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제